- cafead Mar 09, 2022 at 11:22: AM
via An attractive cancer target is going to be in the hot seat at an FDA advisory committee on April 21.
The FDA’s oncologic drugs advisory committee, or ODAC, will specifically discuss a particular class of cancer drugs, known as phosphatidylinositol-3-kinase, or PI3K, inhibitors, that are currently under development in patients with hematologic malignancies, or blood cancers.
article source
The FDA’s oncologic drugs advisory committee, or ODAC, will specifically discuss a particular class of cancer drugs, known as phosphatidylinositol-3-kinase, or PI3K, inhibitors, that are currently under development in patients with hematologic malignancies, or blood cancers.
article source